<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Activated protein C (APC) is a protease with <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> and cytoprotective activities </plain></SENT>
<SENT sid="1" pm="."><plain>APC is neuroprotective in <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent models</z:e> of <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>But, an APC variant with reduced <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> activity, 3K3A-APC, compared to <z:mp ids='MP_0002169'>wild-type</z:mp> APC shows greater neuroprotection with no risk for <z:mp ids='MP_0001914'>bleeding</z:mp> in <z:hpo ids='HP_0001297'>stroke</z:hpo> models </plain></SENT>
<SENT sid="3" pm="."><plain>To determine whether 3K3A-APC exhibits species-dependent neuroprotection similar to that as seen with <z:mp ids='MP_0002169'>wild-type</z:mp> APC, we studied murine and human recombinant 3K3A-APC mutants which show approximately 80% reduced <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> activity </plain></SENT>
<SENT sid="4" pm="."><plain>Murine 3K3A-APC (0.2 mg/kg i.v.) administered at 4 h after embolic <z:hpo ids='HP_0001297'>stroke</z:hpo> improved substantially functional outcome and reduced by 80% the infract volume 7 days after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Human 3K3A-APC was neuroprotective after embolic <z:hpo ids='HP_0001297'>stroke</z:hpo> in mice, but at significantly higher concentrations (i.e. 2 mg/kg i.v.) </plain></SENT>
<SENT sid="6" pm="."><plain>Species-dependent neuroprotection, i.e. murine &gt; human 3K3A-APC, was confirmed in a mouse model of permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>Human 3K3A-APC had by fivefold greater cytoprotective activity than murine 3K3A-APC in oxygen-<z:chebi fb="105" ids="17234">glucose</z:chebi> deprivation model in human brain endothelial cells, whereas murine 3K3A-APC was by 2.5-fold more potent than human 3K3A-APC in a mouse model of <z:chebi fb="0" ids="31882">NMDA</z:chebi>-induced neuronal <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="8" pm="."><plain>Thus, 3K3A-APC exhibits species-dependent neuroprotection which should be taken into account when designing human trials for <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> with APC mutants </plain></SENT>
</text></document>